Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indium-111-2IT-BAD-m170
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Indium-111-2IT-BAD-m170 is a radiolabeled monoclonal antibody-based radioimmunoconjugate designed for imaging and dosimetry in cancer patients, particularly those with metastatic prostate cancer. The drug consists of the murine monoclonal antibody m170, which targets adenocarcinoma cells, conjugated via the chelator 2-[p-(bromoacetamido)benzyl]-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (BAD) and 2-iminothiolane (2IT), to the radionuclide indium-111. Its primary mechanism involves specific binding to tumor-associated antigens on adenocarcinoma cells; after intravenous administration, it enables gamma camera imaging of metastatic lesions due to emission from indium-111. This agent is used for patient selection and dosimetry prior to therapeutic administration of yttrium-90-labeled analogs. It has been studied in phase I clinical trials for targeting and palliation in androgen-independent metastatic prostate cancer[1][3][5].
- Other names
- 111In-2IT-BAD-m170
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on indium-111-2IT-BAD-m170.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indium-111-2IT-BAD-m170.